From research to
clinical reality.
Aceso Plasma has built a foundation of independently validated research, government-funded development, and strategic investment. Here's where we've been — and where we're going.
Development stage
Pre-Clinical Research
Completed 2022
SBIR Funding
Phase I & II complete
Series A Initial Tranche
Closed July 2025
V2 Development & FDA Submission
In progress · 2026
Clinical Trials & FDA Clearance
Upcoming
Aceso Plasma is an investigational device. The device is not currently cleared or approved for clinical use.
A track record of
delivering on commitments.
From the first government order to SBIR completion and the closing of our initial Series A tranche — every milestone delivered on time and on budget.
2020
January
Government Order Fulfilled — $310K
Fulfilled a $310,000 order for two Aceso Plasma Generator units from a government agency — establishing the first commercial transaction and demonstrating the device's readiness for field evaluation.
2020
Feb – Jun
SBIR Phase I & Phase II Awarded — $1.55M
Awarded $1.55M in combined SBIR Phase I and Phase II funding by the US Air Force to conduct research studies across wound healing, antimicrobial efficacy, burn wound care, and chemical agent decontamination.
2022
February
All Four SBIR Research Studies Completed
Completed four independent research studies — all on time and on budget — at Wake Forest Institute of Regenerative Medicine, MedStar Georgetown Research Institute, US Army CCDC CBC, and Edgewood Chemical Biological Center. Results established a comprehensive pre-clinical evidence base across wound healing, disinfection, burn care, and CBRN decontamination.
2025
July
Series A Initial Tranche Closed — Led by Stony Lonesome Group
Successfully closed the initial tranche of our Series A Preferred financing, led by Stony Lonesome Group — a proven early-stage defense and dual-use investor with 14 years of mission-focused investment. Funding supports the next phase of clinical development, regulatory advancement, and production development.
Read announcement on Soldier Systems DailyActive development
across four fronts.
Four parallel workstreams are underway in 2026 — advancing the device, the regulatory pathway, and the clinical leadership team simultaneously.
2026
June
Version 2 Prototypes — Device & Tips
Contract manufacturer Synectic is completing Version 2 prototypes for both the Aceso Plasma Generator and its interchangeable tips. Testing is scheduled to begin immediately upon completion — including spectroscopy, petri dish, and animal laboratory evaluations to validate performance improvements.
In progress2026
June
FDA Breakthrough Designation Submission
Preparing a Breakthrough Device Designation submission to the FDA. If received, Breakthrough Designation will provide clarity on the regulatory pathway, facilitate more frequent interaction with the FDA during development, and create significant marketing and credibility opportunities for the company.
Submission being prepared2026
May
Chief Medical Officer Appointed — Dr. Trip Johnson
Dr. Trip Johnson, a retired physician from the Joint Medical Augmentation Unit (JMAU), has joined Aceso Plasma as Chief Medical Officer. Dr. Johnson brings deep experience in military medicine and special operations medical support, and will chair the company's newly forming Physician Advisory Board.
Completed2026
2026
Physician Advisory Board — Formation Underway
Identifying candidates for a 2-3 physician Physician Advisory Board to be chaired by CMO Dr. Trip Johnson. The board will advise on strategic clinical issues, help communicate the unmet needs in current wound care, and guide Aceso's clinical positioning as the company advances toward FDA clearance.
Candidates being identifiedThe road to
FDA clearance.
The following milestones represent Aceso Plasma's current development roadmap. Timelines are targets and subject to change.
TBD
Upcoming
Clinical Trials — MedStar Georgetown Research Institute
Clinical trials are set to begin at MedStar Georgetown Research Institute for chronic wounds and ESKAPE pathogen-infected wounds — the primary FDA clearance pathway for the Aceso Plasma Generator.
TBD
Upcoming
ESKAPE Pathogen Animal Study
Infected wound healing animal study focused on ESKAPE pathogens — providing additional pre-clinical data to support the FDA De Novo application for the chronic wound care indication.
TBD
Upcoming
FDA Clearance — Chronic Wound Care Indication
Pursuing FDA De Novo clearance for the chronic wound care indication — the primary commercial pathway enabling clinical adoption across wound care centers, hospitals, and surgical settings.
TBD
Upcoming
Decon Chamber — Engineering & High-Level Disinfection Certification
Advancing the Aceso Decontamination Chamber from proof-of-concept prototype to engineered product, targeting FDA High-Level Disinfection Certification for use in military and medical settings.
Third-party recognition of our progress.
"Aceso Plasma Inc., which develops cold plasma medical and decontamination technology, today announced it has successfully closed a Series A Preferred funding round... led by Stony Lonesome Group, LLC. This milestone will support the next phase of clinical trials, regulatory advancement, and production development."
Interested in
where we're headed?
We are actively building relationships with accredited investors, clinical partners, and military collaborators. If you'd like to learn more about Aceso Plasma's development roadmap, we'd love to connect.